A method for biotransformation synthesis of ethylhexylglycerol and a dedicated whole-cell catalyst
By mutating the amino acid residues of epoxide hydrolase, building high-active mutant proteins and introducing recombinant microorganisms, the problem of low catalytic activity in the existing technology is solved, and the efficient bioconversion and synthesis of ethylhexylglycerol is achieved, improving the improvement of the high-efficiency bioconversion and synthesis of ethylhexylglycerol Productivity and environmental protection.
Patent Information
- Application Number
- CN202411006106.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-25
AI Technical Summary
In the prior art, the catalytic activity of epoxide hydrolase is low, resulting in low bioconversion and synthesis efficiency of ethylhexylglycerol.
By mutating the amino acid residues at positions 228, 308 and 311 of the wild-type epoxide hydrolase, mutant proteins with enhanced catalytic activity are constructed and introduced into recombinant microorganisms to form whole-cell catalysts to catalyze stimulation Basic glycidyl ether forms ethylhexylglycerol.
It significantly improves the yield and catalytic efficiency of ethylhexylglycerol, optimizes the bioconversion and synthesis process, reduces production costs, and achieves green and environmentally friendly and efficient synthesis.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and particularly relates to a method for synthesizing ethylhexylglycerol through biological transformation and a special whole-cell catalyst. Background Art
[0002] Epoxide hydrolases (EHs; EC 3.3.2.3) can be divided into α / β hydrolases, limonene epoxide hydrolases, and leukotriene A4 hydrolases based on their catalytic mechanisms. Among them, EHs belonging to the α / β hydrolase fold family are the most numerous. EHs hydrolyze their substrates via a two-step mechanism, involving the formation and hydrolysis of a covalent intermediate. This process catalyzes the hydrolysis of epoxides to the corresponding vicinal diols without relying on cofactors. EHs have been discovered in many organisms, including mammals, plants, insects, fungi, and bacteria. In recent years, EHs have garnered significant attention due to their mild and environmentally friendly reactions, exemplified by the catalytic production of enantiomeric epoxides from racemates.
[0003] Ethylhexylglycerin, also known as isooctylglyceryl ether or octyloxyglycerin, is a synthetic representative of 1-alkyl glyceryl ethers. It contains high-purity glyceryl ethers and is a completely transparent liquid with a slight distinctive odor. As a multifunctional cosmetic ingredient, ethylhexylglycerin has lubricating, moisturizing, and nourishing properties. It also has a deodorizing effect by inhibiting the growth and reproduction of odor-causing bacteria on the skin surface. Furthermore, ethylhexylglycerin has antiseptic properties, and mixing it with traditional preservatives can significantly enhance its antiseptic properties.
[0004] Currently, ethylhexylglycerin can be produced through chemical synthesis and biotransformation. Chemical synthesis of ethylhexylglycerin is subject to numerous side reactions, resulting in impurities that are difficult to separate and increase production costs. Biotransformation, on the other hand, offers simple reaction conditions, environmental friendliness, low cost, and high specificity, making it an ideal method for producing ethylhexylglycerin. Summary of the Invention
[0005] The technical problem solved by the invention is to improve the catalytic efficiency of epoxide hydrolase.
[0006] In order to solve the above technical problems, in a first aspect, the present invention provides an epoxide hydrolase mutant protein, which is any one of the following A1-A3:
[0007] The protein shown in A1) is a protein having epoxide hydrolase activity obtained by mutating at least one of the amino acid residues 228, 308, and 311 of the amino acid sequence of the wild-type epoxide hydrolase;
[0008] The protein shown in A2) is a fusion protein obtained by linking the protein shown in A1 with a protein having a targeting function;
[0009] The protein shown in A3) is a fusion protein obtained by adding a tag sequence to the end of the amino acid sequence of the protein shown in A1.
[0010] Among the mutant proteins described above, the protein represented by A1) is any one of the following:
[0011] The protein described in A1-1) is a protein having epoxide hydrolase activity obtained by mutating the amino acid residue 228 of the amino acid sequence of wild-type epoxide hydrolase;
[0012] A1-2) The protein is obtained by mutating amino acid residues 228 and 308 of the amino acid sequence of wild-type epoxide hydrolase to obtain a protein having epoxide hydrolase activity;
[0013] A1-3) The protein described is a protein having epoxide hydrolase activity obtained by mutating amino acid residues 228 and 311 of the amino acid sequence of a wild-type epoxide hydrolase;
[0014] A1-4) The protein is obtained by mutating residues 228, 308, and 311 of the amino acid sequence of wild-type epoxide hydrolase to obtain a protein having epoxide hydrolase activity;
[0015] A1-5) The protein is obtained by mutating amino acid residues 308 and 311 of the amino acid sequence of wild-type epoxide hydrolase to obtain a protein having epoxide hydrolase activity;
[0016] The protein described in A1-6) is obtained by mutating the amino acid residue 308 of the amino acid sequence of the wild-type epoxide hydrolase to obtain a protein having epoxide hydrolase activity.
[0017] In the mutant protein described above, the mutations of the amino acid residues are as follows:
[0018] The amino acid residue at position 228 is mutated to change Y at position 228 to A;
[0019] The amino acid residue at position 308 is mutated to convert F at position 308 to A;
[0020] The amino acid residue at position 311 is mutated to convert F at position 311 to A.
[0021] In the mutant protein described above, the wild-type epoxide hydrolase is any one of the following:
[0022] B1, the protein shown in Sequence 1 of the Sequence Listing;
[0023] B2, a protein represented by a sequence having 80% or 90% or greater homology with SEQ ID NO: 1 except for amino acid residues 228, 308, and 311;
[0024] Or, the amino acid sequence of the epoxide hydrolase mutant protein shown in A1-1) is sequence 2;
[0025] Or, the amino acid sequence of the epoxide hydrolase mutant protein shown in A1-2) is sequence 3;
[0026] Or, the amino acid sequence of the epoxide hydrolase mutant protein shown in A1-3) is Sequence 4;
[0027] Or, the amino acid sequence of the epoxide hydrolase mutant protein shown in A1-4) is Sequence 6;
[0028] Alternatively, the amino acid sequence of the epoxide hydrolase mutant protein shown in A1-5) is Sequence 5.
[0029] In the above, the enzymatic activity of the epoxide hydrolase mutant protein is greater than that of the wild-type epoxide hydrolase.
[0030] In a second aspect, the present invention provides a biological material related to the mutant protein described in the first aspect, wherein the biological material is any one of the following C1) to C8):
[0031] C1) a nucleic acid molecule encoding the mutant protein according to the first aspect;
[0032] C2) an expression cassette containing the nucleic acid molecule described in C1);
[0033] C3) a recombinant vector containing the nucleic acid molecule described in C1);
[0034] C4) a recombinant vector containing the expression cassette described in C2);
[0035] C5) a recombinant microorganism containing the nucleic acid molecule described in C1);
[0036] C6) a recombinant microorganism containing the expression cassette described in C2);
[0037] C7) a recombinant microorganism containing the recombinant vector described in C3);
[0038] C8) A recombinant microorganism containing the recombinant vector described in C4).
[0039] In the above-mentioned related biological materials, the recombinant microorganism is Escherichia coli.
[0040] The recombinant microorganism described above is prepared according to a method comprising the following steps: introducing the gene encoding the mutant protein described in the first aspect into the host bacteria to obtain the recombinant microorganism.
[0041] In the above, the host bacteria is further specifically Escherichia coli E. coli BL21 (DE3).
[0042] In a third aspect, the present invention provides use of the protein of the first aspect or the biomaterial of the second aspect in any of the following:
[0043] D1) Preparation of whole-cell catalysts;
[0044] D2) synthetic ethylhexylglycerin;
[0045] D3) Increase the production of ethylhexylglycerol.
[0046] In the above, the catalytic substrate required for synthesizing ethylhexylglycerol or increasing the yield of ethylhexylglycerol or the catalytic substrate of the whole-cell catalyst is octyl glycidyl ether.
[0047] In a fourth aspect, the present invention provides a whole-cell catalyst prepared according to a method comprising the following steps: inducing expression of the recombinant microorganism described in the second aspect, collecting the cells, and obtaining a whole-cell catalyst;
[0048] Alternatively, a method for producing ethylhexylglycerol or increasing the yield of ethylhexylglycerol comprises the following steps: using the whole-cell catalyst as a catalyst to catalyze the substrate octyl glycidyl ether to obtain ethylhexylglycerol;
[0049] Alternatively, a method for producing ethylhexylglycerin or increasing the yield of ethylhexylglycerin comprises the following steps:
[0050] E1) subjecting the wild-type epoxide hydrolase amino acid sequence in the first aspect to the mutation described in the first aspect to obtain an epoxide hydrolase mutant protein;
[0051] E2) introducing the gene encoding the epoxide hydrolase mutant protein into a host bacterium to obtain a recombinant microorganism;
[0052] E3) inducing expression in the recombinant microorganism, collecting the cells to obtain a whole-cell catalyst, and using the whole-cell catalyst to catalyze the reaction of a substrate, octyl glycidyl ether, to obtain ethylhexylglycerol;
[0053] Or use of a substance that causes the amino acid sequence of the wild-type epoxide hydrolase in the first aspect to undergo the mutation described in the first aspect in producing ethylhexylglycerol or increasing the yield of ethylhexylglycerol.
[0054] In the above method, the catalytic pH value is 6.0-8.0;
[0055] The catalytic conditions are: reaction speed 150-200 rpm, reaction temperature 30-37°C, reaction time 2-24 h;
[0056] In the catalysis, the ratio of the recombinant microorganism to the substrate octyl glycidyl ether is 10-100 g / L:2.1 M.
[0057] The optimal pH of the catalytic reaction buffer was 7.0; the optimal bacterial concentration of the catalytic reaction was 12.5 g / L; the optimal rotation speed of the catalytic reaction was 160 rpm; the optimal temperature of the catalytic reaction was 33 °C; and the optimal reaction time of the catalytic reaction was 7 h.
[0058] EHs, as an important biocatalyst, can convert epoxides into vicinal diols under mild conditions, and are particularly suitable for the conversion of racemates. This invention utilizes molecular biology techniques and protein engineering to perform site-directed mutagenesis on the active center of EHs, successfully improving the enzyme's catalytic efficiency. This overcomes the low catalytic activity problem in existing technologies and provides a new pathway for the green biosynthesis of ethylhexylglycerol. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] Figure 1 This is the synthetic route for ethylhexylglycerol.
[0060] Figure 2 The protein expression of epoxide hydrolase; a: protein expression of wild-type epoxide hydrolase NaEH; b-g: protein expression of epoxide hydrolase mutants; M: Marker; 1-4: whole cells before induction, whole cells after induction, cell supernatant after induction, and cell pellet.
[0061] Figure 3 is the catalytic efficiency of epoxide hydrolase NaEH at different bacterial concentrations.
[0062] Figure 4 is the conversion rate of substrate by different mutants. DETAILED DESCRIPTION
[0063] The present invention will be further described in detail below in conjunction with specific embodiments. The examples provided are only for illustrating the present invention and are not intended to limit the scope of the present invention. The examples provided below can serve as a guide for further improvements by those skilled in the art and are not intended to limit the present invention in any way.
[0064] Unless otherwise specified, the experimental methods in the following examples are conventional methods and were performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials and reagents used in the following examples, unless otherwise specified, were all commercially available.
[0065] Unless otherwise specified, the quantitative tests in the following examples were performed three times, and the results were averaged.
[0066] The plasmids and strains in the following examples are as follows:
[0067] Host cells E. coli DH5α and E. coli BL21 (DE3) were purchased from Lanjieke Technology Co., Ltd.
[0068] The cloning vector was constructed by the Hangzhou Branch of Beijing Qingke Biotechnology Co., Ltd., and the expression strain was constructed by our company.
[0069] Experimental reagents used in the following examples include: PrimeSTAR® Max DNA polymerase, purchased from Takara (Dalian); Dpn I enzyme, purchased from Thermo Scientific; and a plasmid miniprep kit, purchased from Shanghai Biotech Co., Ltd. PCR primer synthesis and DNA sequencing were performed by Beijing Qingke Biotechnology Co., Ltd., Hangzhou Branch.
[0070] The experimental culture medium in the following examples is:
[0071] LB liquid medium: peptone 10 g / L, yeast powder 5 g / L, sodium chloride 10 g / L, pH 7.0.
[0072] LB solid medium: LB liquid medium + 1.5% to 2% (mass ratio) agar powder.
[0073] The experimental buffer in the following examples is:
[0074] 100 mM phosphate saline (PBS) buffer: 2.0 g KCl, 80.0 g NaCl, 36.3 g Na2HPO4·12H2O, 2.4 g KH2PO4, dilute to 1 L with deionized water.
[0075] 20 mM phosphate saline (PBS) buffer: 200 mL of 100 mM phosphate saline (PBS) buffer, 700 mL of deionized water, adjust the pH to 7.0, and then dilute to 1 L with deionized water.
[0076] Normal saline: 9 g NaCl, dilute to 1 L with deionized water.
[0077] Protein electrophoresis buffer: 1 g SDS, 14.4 g glycine, 3.03 g tris(hydroxymethyl)aminomethane, and dilute to 1 L with deionized water.
[0078] Gel destaining solution: 100 mL glacial acetic acid, 50 mL ethanol, dilute to a total volume of 1 L with deionized water.
[0079] The structural formulas of the compounds used in the following examples are shown in Table 1:
[0080] Table 1 shows the structural formula of the compound
[0081]
[0082] Figure 1 This is the synthetic route for ethylhexylglycerol.
[0083] Example 1. Preparation of Whole-Cell Catalyst Expressing Epoxide Hydrolase
[0084] 1. Preparation of recombinant vector expressing wild-type epoxide hydrolase
[0085] To obtain the epoxide hydrolase (EHs) NaEH from Novosphingobium aromaticivorans, the gene sequence (GenBank accession number ABD26703.1) was retrieved from the NCBI database. Beijing Qingke Biotechnology Co., Ltd. was commissioned to synthesize the gene and insert it into the pET30a(+) vector to construct a glycerol strain, E. coli DH5α pET30a(+)-NaEH. The strain was shaken by streaking on LB plates and selecting a single colony. The strain was then preserved and the plasmid extracted.
[0086] In order to enable E. coli BL21 (DE3) to express EHs, the plasmid extracted above was transformed into the strain as follows:
[0087] (1) Take out the competent E. coli BL21(DE3) cells from the -80℃ freezer and thaw them on ice.
[0088] (2) Mix 5 μL of recombinant plasmid pET30a(+)-NaEH with 50 μL of E. coli BL21(DE3) competent cells, shake gently to allow the two to fully contact, and then place on ice for 30 min.
[0089] (3) Heat shock the mixture in a 42°C water bath for 90 seconds. After the heat shock is complete, immediately place it back on ice to cool for 3 to 5 minutes.
[0090] (4) Add 600 μL of pre-chilled LB medium to each tube of the mixture and incubate at 37°C and 180 rpm for 1 h to help the cells recover.
[0091] (5) Take 50-100 μL of bacterial suspension and evenly spread it on the LB solid culture medium plate containing resistance. After incubating the plate at 37°C for 20-30 minutes, invert it and culture it overnight to screen out the colonies that have successfully introduced the plasmid.
[0092] After the above steps (1) to (5), the genetically engineered bacteria E. coli BL21(DE3) pET30a(+)-NaEH capable of expressing EHs was successfully constructed.
[0093] pET30a(+)-NaEH is a plasmid obtained by inserting the coding gene of wild-type epoxide hydrolase NaEH (amino acid sequence is SEQ ID NO: 1) between the NdeI and BamHI restriction sites of the pET30a(+) vector. This is a recombinant vector expressing wild-type epoxide hydrolase.
[0094] 2. Prediction of mutation sites
[0095] Molecular docking analysis predicted four key residue positions. Using site-directed mutagenesis, 15 mutants were designed and constructed to optimize the structure and catalytic efficiency of NaEH. The primers used for these mutants are listed in Table 2 below.
[0096] Table 2 shows the relevant information of the 15 mutants
[0097]
[0098] 3. Construction of recombinant plasmids expressing epoxide hydrolase mutants
[0099] Recombinant plasmids expressing various epoxide hydrolase mutants The coding genes of various epoxide hydrolase mutants were inserted between the NdeI and BamHI restriction sites of the pET30a(+) vector. The resulting plasmids were recombinant vectors expressing various epoxide hydrolase mutants: pET30a(+)-R205A, pET30a(+)-Y228A, pET30a(+)-F308A, pET30a(+)-F311A, pET30a(+)-R205A / Y228A, pET30a(+)-R205A / F308A, pET30a(+)-F311A, pET30a(+)-Y228A / F308A, pET30a(+)-Y228A / F311A. 1A, pET30a(+)-F308A / F311A, pET30a(+)-R205A / Y228A / F308A, pET30a(+)-R205A / Y228A / F311A, pET30a(+)-R205A / F308A / F311A, pET30a(+)-Y228A / F308A / F311A, and pET30a(+)-R205A / Y228A / F308A / F311A.
[0100] Each of the above-mentioned epoxide hydrolase mutants is any of the following:
[0101] The epoxide hydrolase mutant R205A is a mutant obtained by mutating R at position 205 of the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1 to A, while keeping other amino acid residues unchanged.
[0102] The epoxide hydrolase mutant Y228A is a mutant obtained by mutating Y at position 228 of the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1 to A, while keeping other amino acid residues unchanged.
[0103] The epoxide hydrolase mutant F308A is a mutant obtained by mutating the F at position 308 of the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1 to A, while the other amino acid residues remain unchanged.
[0104] The epoxide hydrolase mutant F311A is a mutant obtained by mutating the F at position 311 of the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1 to A, while keeping the other amino acid residues unchanged.
[0105] The epoxide hydrolase mutant R205A / Y228A is a mutant obtained by mutating R at position 205 to A and Y at position 228 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1, while other amino acid residues remain unchanged.
[0106] The epoxide hydrolase mutant R205A / F308A is a mutant obtained by mutating R at position 205 to A and F at position 308 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1, while other amino acid residues remain unchanged.
[0107] The epoxide hydrolase mutant R205A / F311A is a mutant obtained by mutating R at position 205 to A and F at position 311 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1, while other amino acid residues remain unchanged.
[0108] The epoxide hydrolase mutant Y228A / F308A is a mutant obtained by mutating Y at position 228 to A and F at position 308 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1, while other amino acid residues remain unchanged.
[0109] The epoxide hydrolase mutant Y228A / F311A is a mutant obtained by mutating Y at position 228 to A and F at position 311 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1, while other amino acid residues remain unchanged.
[0110] The epoxide hydrolase mutant F308A / F311A is a mutant obtained by mutating the 308th F to A and the 311th F to A of the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in SEQ ID NO: 1, while the other amino acid residues remain unchanged.
[0111] The epoxide hydrolase mutant R205A / Y228A / F308A is a mutant obtained by mutating R at position 205 to A, Y at position 228 to A, and F at position 308 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in Sequence 1, while the other amino acid residues remain unchanged.
[0112] The epoxide hydrolase mutant R205A / Y228A / F311A is a mutant obtained by mutating R at position 205 to A, Y at position 228 to A, and F at position 311 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in Sequence 1, while keeping the other amino acid residues unchanged.
[0113] The epoxide hydrolase mutant R205A / F308A / F311A is a mutant obtained by mutating R at position 205 to A, F at position 308 to A, and F at position 311 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in Sequence 1, while keeping the other amino acid residues unchanged.
[0114] The epoxide hydrolase mutant Y228A / F308A / F311A is a mutant obtained by mutating Y at position 228 to A, F at position 308 to A, and F at position 311 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in Sequence 1, while the other amino acid residues remain unchanged.
[0115] The epoxide hydrolase mutant R205A / Y228A / F308A / F311A is a mutant obtained by mutating R at position 205 to A, Y at position 228 to A, F at position 308 to A, and F at position 311 to A in the amino acid sequence of the wild-type epoxide hydrolase NaEH shown in Sequence 1, while keeping the other amino acid residues unchanged.
[0116] The above-mentioned recombinant plasmids expressing the respective epoxide hydrolase mutants were prepared specifically according to the following method:
[0117] Based on the results of molecular docking, four key amino acid residues were selected, and 15 different mutants were constructed through site-directed mutagenesis. These mutants were designed to improve the performance of epoxide hydrolases (EHs). First, PCR amplification was performed using the NaEH gene in the pET28a(+) vector as a template using the upstream and downstream primers listed in Table 2. The PCR amplification system for each round of reaction consisted of 25 μL of 2× PrimeSTAR® Max DNA polymerase, 1 μL of the upstream primer (10 μM), 1 μL of the downstream primer (10 μM), 1 μL of the pET-28a(+)-NaEH plasmid, and 22 μL of sterile water. The PCR amplification program was as follows: ① initial denaturation at 98°C for 5 min; ② 30 cycles of denaturation at 98°C for 15 s, annealing at 55°C for 5 s, and extension at 72°C for 40 s; ③ a final extension at 72°C for 5 min.
[0118] After the PCR product was confirmed by gel electrophoresis, it was digested with Dpn I enzyme, which specifically cuts the methylated template DNA, thereby removing the original unmutated template. The digestion process was: 17 μL PCR product, 2 μL Buffer and 1 μL Dpn I were treated at 37 °C for 2 h.
[0119] The digested product was introduced into competent E. coli DH5α cells. After transformation, a portion of the cell suspension was evenly spread on LB solid medium containing the corresponding resistance. After overnight incubation, individual colonies were selected from the plate and grown in LB medium supplemented with 50 μg / mL Kan (kanamycin) at 37°C and 180 rpm overnight. One mL of the bacterial suspension was used for DNA analysis; another 1 mL was used for bacterial culture storage; and 3 mL was used for plasmid extraction. Plasmid extraction was performed according to the kit instructions. Sequencing confirmed the correctness of the plasmid.
[0120] 4. Inducible expression and identification of epoxide hydrolase mutants
[0121] 1) Construction of recombinant bacteria
[0122] The recombinant plasmids expressing the respective epoxide hydrolase mutants and the recombinant plasmid expressing the wild-type epoxide hydrolase obtained in 3 above were transformed into E. coli BL21 (DE3) competent cells to obtain recombinant bacteria.
[0123] The plasmids of the recombinant bacteria were extracted and sent for sequencing. The recombinant bacteria with the target plasmids were named as follows: BL21 / pET30a(+)-R205A, BL21 / pET30a(+)-Y228A, BL21 / pET30a(+)-F308A, BL21 / pET30a(+)-F311A, BL21 / pET30a(+)-R205A / Y228A, BL21 / pET30a(+)-R205A / F308A, BL21 / pET30a(+)-R205A / F311A, BL21 / pET30a(+)-Y228A / F308A, BL21 / pET30a(+)-Y228A / F311A, BL21 / pET30a(+)-F308A / F311A, BL21 / pET30a(+)-R205A / Y228A / F308A, BL21 / pET30a(+)-R205A / Y228A / F311A, BL21 / pET30a(+)-R205A / F308A / F311A, BL21 / pET30a(+)-Y228A / F308A / F311A, BL21 / pET30a(+)-R205A / Y228A / F308A / F311A, and BL21 / pET30a(+)-NaEH.
[0124] 2) Induce expression of target protein
[0125] Select a single colony from each recombinant strain and inoculate it into 5 mL of LB medium containing Kan (kanamycin). Incubate overnight at 37°C and 180 rpm to allow for full bacterial growth. Inoculate 200 mL of LB medium containing Kan at a 1% (v / v) volume ratio from the overnight culture. Incubate at 37°C and 180 rpm for approximately 3–4 hours, until the optical density (OD600) reaches 0.6–0.8, indicating an appropriate bacterial concentration.
[0126] At this point, IPTG (isopropylthiogalactoside, an inducer used to initiate recombinant protein expression) was added to a final concentration of 1 mM. The temperature was then adjusted to 25°C, the rotational speed was reduced to 150 rpm, and the culture was continued overnight to induce recombinant protein expression. The following day, the induced bacterial solution was centrifuged at 12,000 rpm for 10 minutes at 4°C to collect the bacterial cells. The collected bacterial cells were then washed once with physiological saline and centrifuged again at 4°C and 12,000 rpm for 10 minutes. The supernatant was removed, retaining only the individual bacterial pellets to obtain the whole-cell catalysts prepared from each recombinant bacterium.
[0127] Protein purity was detected by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) method, and the specific steps are as follows:
[0128] (1) The collected bacteria were suspended in 0.02 M PBS buffer to a concentration of 10 OD (each OD is equivalent to 1 g / L of bacteria), and the cells were disrupted at 4 °C and 1000 bar. Repeat 1 to 2 times to ensure that the intracellular proteins were released.
[0129] (2) Take 40 μL of the supernatant and precipitate before / after induction (bacterial concentration is about 10 OD), after disruption, add 10 μL of 5× protein loading buffer respectively, and heat treat at 95 °C for 15 min to ensure protein denaturation and linearization.
[0130] (3) During the electrophoresis loading phase, 5 μL of protein marker was used, and the sample loading volume was 10 μL. During electrophoresis, the voltage was set between 80 and 120 V, and electrophoresis was continued until the bromophenol blue indicator moved to approximately 1 cm from the bottom edge of the separation gel.
[0131] (4) After electrophoresis, remove the gel mold and place the gel plate in a culture dish filled with distilled water. Use a gel stripper to gently peel off the gel. Gently wash the gel with distilled water 1 to 2 times and place it in a clean culture dish.
[0132] (5) Add staining solution to the culture dish until the gel is submerged, heat for 1-2 minutes, and then let it stand at room temperature for 30 minutes. After staining is completed, the staining solution will be recycled.
[0133] (6) Add decolorizing solution to the culture dish for decolorization. Replace the decolorizing solution every 2 hours until the protein bands are clear.
[0134] The results are as follows Figure 2 As shown, each recombinant strain produced a protein of the expected target size (45.0 kD). All mutant proteins were expressed soluble in the cells at substantial levels. This indicates that both wild-type and mutant NaEH proteins can be abundantly synthesized in host cells.
[0135] Example 2: Application of Whole-Cell Catalyst Expressing Epoxide Hydrolase
[0136] 1. Whole-cell catalysis
[0137] The activities of wild-type epoxide hydrolases (EHs) and various epoxide hydrolase mutants were verified using a whole-cell catalytic assay.
[0138] 1. BL21 / pET30a(+)-NaEH expressing wild-type epoxide hydrolases (EHs) as whole-cell catalysts
[0139] The whole-cell catalyst prepared from BL21 / pET30a(+)-NaEH in Example 1 (4) was resuspended in buffers of varying pH values to a concentration of 10 to 100 g / L. 2.1 M of the substrate, octyl glycidyl ether, was then added and thoroughly mixed to initiate the catalytic reaction. The reaction liquid was collected. The reaction conditions were a rotation speed between 150 and 200 rpm, a reaction temperature between 30 and 37°C, and a reaction time of 2 to 24 hours. Samples of the reaction liquid were collected at various time points during the reaction. BL21 / pET30a(+) (recombinant E. coli obtained by transforming the pET30a(+) vector into E. coli) was used as a control.
[0140] GC detection analysis method:
[0141] Gas chromatography (GC) analysis was performed to analyze the content of ethylhexylglycerol and octyl glycidyl ether in the whole-cell catalytic reaction solution. 200 μL of the catalytic reaction solution was added to 600 μL of acetonitrile, mixed thoroughly, and centrifuged at 12,000 rpm for 2 minutes. The organic phase was collected, dried over anhydrous sodium sulfate, and filtered through a 0.22 μm organic filter.
[0142] For gas chromatography analysis, an HP-5 column (30 m × 0.250 mm × 0.10 μm) was used, nitrogen was used as the carrier gas, a flame ionization detector (FID) was used as the detector, a split ratio of 20:1, and an injection volume of 1 μL. The content of each substance in the sample was determined using the external standard method.
[0143] To ensure the accuracy and reproducibility of the test results, a standard curve was prepared. The following steps were taken: 1.2 mL of ethylhexylglycerol standard (Shanghai MacLean Biochemical Technology Co., Ltd., E858034) and 1.5 mL of octyl glycidyl ether were accurately weighed, each added to 10 mL of acetonitrile solution, mixed thoroughly, and then diluted 50-fold with n-hexane to prepare a standard stock solution with a mass concentration of 2.7 g / L of ethylhexylglycerol and 2.4 g / L of octyl glycidyl ether. Standard working solutions of varying concentrations were prepared by serial dilution.
[0144] The calibration function of substrate octyl glycidyl ether is: y=820597x+6915.7, R 2 =0.9997, x is the substrate concentration (g / L), and y is the peak area.
[0145] The calibration function of the product ethylhexylglycerin is: y=693548x-70424, R 2 =0.9956, x is the product concentration (g / L), and y is the peak area.
[0146] Substrate conversion rate = product molar concentration / input substrate molar concentration*100%
[0147] result:
[0148] The pH of the catalytic reaction buffer was in the range of 6.0 to 8.0, with the optimal pH being 7.0; the bacterial concentration of the catalytic reaction was between 10 and 100 g / L, with the optimal bacterial concentration being 12.5 g / L; the rotation speed of the catalytic reaction was between 150 and 200 rpm, with the optimal speed being 160 rpm; the reaction temperature of the catalytic reaction was between 30 and 37 °C, with the optimal temperature being 33 °C; and the reaction time of the catalytic reaction was between 2 and 24 h, with the optimal reaction time being 7 h.
[0149] Under the optimal catalytic conditions, the results of substrate conversion rates at different bacterial concentrations are as follows: Figure 3As shown in the results of a BL21 / pET30a(+)-NaEH assay, after 7 hours of catalysis, the catalytic activity of NaEH increased with increasing bacterial cell concentration (1-12.5 g / L), reaching a peak of 88.29% at a cell concentration of 12.5 g / L. However, further increases in cell concentration did not result in further increases in catalytic activity, indicating that enzyme quantity is no longer the limiting factor. The key to further improving catalytic efficiency lies in increasing the enzyme's activity, rather than simply increasing its concentration.
[0150] Therefore, NaEH achieved the best catalytic efficiency at a cell concentration of 12.5 g / L.
[0151] 2. Recombinant bacteria expressing epoxide hydrolase mutants as whole-cell catalysts
[0152] In order to evaluate the catalytic efficiency of the mutant NaEH towards substrates, the present invention conducted a whole-cell catalytic assay.
[0153] The recombinant bacteria expressing the epoxide hydrolase mutants were used to prepare whole-cell catalysts according to the method of 4 in Example 1, and catalysis was carried out under the optimal catalytic conditions according to the method of 1 above.
[0154] The substrate conversion results are as follows Figure 4 As shown in the figure, under conditions of a bacterial cell concentration of 12.5 g / L and a catalytic duration of 7 hours, the five specific mutants, Y228A, Y228A / F308A, Y228A / F311A, F308A / F311A, and Y228A / F308A / F311A, significantly improved the conversion of the substrate octyl glycidyl ether compared to wild-type NaEH, reaching 100%. Wild-type NaEH, on the other hand, achieved a conversion of 87.48% for the same substrate. This indicates that these mutants have superior catalytic abilities for the substrate compared to the wild-type.
[0155] The above results show that the catalytic efficiency of NaEH can be effectively improved through site-directed mutagenesis of amino acid residues, especially when the key sites Y228A, F308A and F311A are involved, the mutant enzyme exhibits stronger catalytic activity.
[0156] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be practiced over a wide range of parameters, concentrations, and conditions without departing from the spirit and scope of the present invention and without unnecessary experimentation. Although specific embodiments have been given herein, it should be understood that further modifications may be made to the present invention. In summary, this application is intended to encompass any variations, uses, or improvements to the present invention, including those made by conventional techniques known in the art that depart from the scope of the present invention. Applications of the essential features may be made within the scope of the following claims.
Claims
1. An epoxide hydrolase mutant protein, which is any one of the following A1-A2: A1) the amino acid sequence of the epoxide hydrolase mutant protein is sequence 2, sequence 3, sequence 4, sequence 5 or sequence 6; A2) The epoxide hydrolase mutant protein is a fusion protein obtained by adding a tag sequence to the end of the amino acid sequence of the protein described in A1.
2. The biomaterial related to the epoxide hydrolase mutant protein according to claim 1, characterized in that: The relevant biological material is any one of the following C1) to C8): C1) a nucleic acid molecule encoding the epoxide hydrolase mutant protein according to claim 1; C2) an expression cassette containing the nucleic acid molecule described in C1); C3) a recombinant vector containing the nucleic acid molecule described in C1); C4) a recombinant vector containing the expression cassette described in C2); C5) a recombinant microorganism containing the nucleic acid molecule described in C1); C6) a recombinant microorganism containing the expression cassette described in C2); C7) a recombinant microorganism containing the recombinant vector described in C3); C8) A recombinant microorganism containing the recombinant vector described in C4).
3. The biological material according to claim 2, characterized in that: The recombinant microorganism is Escherichia coli.
4. The biological material according to claim 2 or 3, characterized in that: The recombinant microorganism is prepared according to a method comprising the following steps: introducing the coding gene of the epoxide hydrolase mutant protein according to claim 1 into a host bacterium to obtain the recombinant microorganism.
5. Use of the epoxide hydrolase mutant protein according to claim 1 or the biomaterial according to claim 2 or 3 in any of the following: D1) Preparation of whole-cell catalysts; D2) synthetic ethylhexylglycerin; D3) Increase the production of ethylhexylglycerol.
6. A whole-cell catalyst prepared by a method comprising the following steps: inducing expression of the recombinant microorganism in claim 2, collecting the microorganism, and obtaining a whole-cell catalyst.
7. A method for producing ethylhexylglycerol or increasing the yield of ethylhexylglycerol, comprising the steps of: E1) introducing the gene encoding the epoxide hydrolase mutant protein of claim 1 into a host bacterium to obtain a recombinant microorganism; E2) inducing expression of the recombinant microorganism, collecting the bacterial cells to obtain a whole-cell catalyst, and using the whole-cell catalyst to catalyze the substrate octyl glycidyl ether to obtain ethylhexylglycerol.
8. The method according to claim 7, characterized in that: The catalytic pH value is 6.0-8.0; The catalytic conditions are: reaction speed 150-200 rpm, reaction temperature 30-37°C, reaction time 2-24 h; In the catalysis, the ratio of the recombinant microorganism to the substrate octyl glycidyl ether is 10-100 g / L:2.1M.
Citation Information
Patent Citations
Enantioselective epoxide hydlrolase and method for preparing and enantiopure epoxide using the same
CN103468658A
Epoxide hydrolase mutant, engineering bacteria and application of epoxide hydrolase mutant
CN104745547A
Epoxide hydrolase mutant with improved catalytic efficiency, and preparation method of epoxide hydrolase mutant
CN113373128A
